| 000 | 01909 a2200577 4500 | ||
|---|---|---|---|
| 005 | 20250514022144.0 | ||
| 264 | 0 | _c20020405 | |
| 008 | 200204s 0 0 eng d | ||
| 022 | _a1043-1802 | ||
| 024 | 7 |
_a10.1021/bc010021y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHamann, Philip R | |
| 245 | 0 | 0 |
_aGemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. _h[electronic resource] |
| 260 |
_bBioconjugate chemistry _c |
||
| 300 |
_a47-58 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAminoglycosides |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntigens, CD _ximmunology |
| 650 | 0 | 4 |
_aAntigens, Differentiation, Myelomonocytic _ximmunology |
| 650 | 0 | 4 | _aCross-Linking Reagents |
| 650 | 0 | 4 | _aGemtuzumab |
| 650 | 0 | 4 | _aHL-60 Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotoxins _xtherapeutic use |
| 650 | 0 | 4 | _aIndicators and Reagents |
| 650 | 0 | 4 |
_aLeukemia, Myeloid _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 | _aNeoplasm Transplantation |
| 650 | 0 | 4 | _aSialic Acid Binding Ig-like Lectin 3 |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aHinman, Lois M | |
| 700 | 1 | _aHollander, Irwin | |
| 700 | 1 | _aBeyer, Carl F | |
| 700 | 1 | _aLindh, Delores | |
| 700 | 1 | _aHolcomb, Ryan | |
| 700 | 1 | _aHallett, William | |
| 700 | 1 | _aTsou, Hwei-Ru | |
| 700 | 1 | _aUpeslacis, Janis | |
| 700 | 1 | _aShochat, Dan | |
| 700 | 1 | _aMountain, Andrew | |
| 700 | 1 | _aFlowers, David A | |
| 700 | 1 | _aBernstein, Irwin | |
| 773 | 0 |
_tBioconjugate chemistry _gvol. 13 _gno. 1 _gp. 47-58 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/bc010021y _zAvailable from publisher's website |
| 999 |
_c11703399 _d11703399 |
||